Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint & Alavert

This article was originally published in The Tan Sheet

Executive Summary

WellPoint Health Networks this month will mail three $10-off coupons for Wyeth's orally disintegrating loratadine to 438,000 members who received a prescription for a second-generation antihistamine within the past six months. Program marks WellPoint's first broad-scale couponing effort, although firm notes it has "dabbled" with coupons for OTC H2 antagonists in the past. WellPoint, which petitioned FDA to switch second-generation antihistamines OTC, says it approached Schering, Wyeth, McNeil about a cooperative marketing program for OTC loratadine and will split the couponing campaign's costs with Wyeth. In approving Alavert Dec. 23, FDA directed Wyeth to submit introductory promotional materials (1"The Tan Sheet" Dec. 23, 2002, p. 5). FDA says it also asked Schering to submit promotional materials for OTC Claritin; however, the request was made more informally and was not stated in the approval letters...

You may also be interested in...



Alavert promotions

Wyeth Consumer Healthcare is partnering with Aetna to provide Alavert coupons, information on OTC loratadine to roughly 475,000 of Aetna's commercial members who have received an Rx for any non-sedating antihistamine in the past year, healthcare provider announces Feb. 5. Mailings are slated to begin in February and end in early April, firm says. Wyeth also has engaged in an Alavert marketing program with WellPoint (1"The Tan Sheet" Jan. 6, 2003, In Brief)...

Wyeth Alavert Approval Sparks Loratadine Price Wars, Fight For OTC Share

Wyeth Consumer Healthcare is staking a claim to the OTC loratadine market with Alavert pricing of 56¢ to $1 per orally disintegrating tablet and high-value coupons

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel